The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Duke University
Sponsor:
Information provided by (Responsible Party):
Andrew J. Armstrong, MD, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT01513733
First received: January 17, 2012
Last updated: May 14, 2014
Last verified: May 2014
  Purpose

The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon which to improve upon. Thus, the primary objective of this study is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).


Condition Intervention Phase
Prostate Cancer
Drug: tasquinimod
Drug: tasquinimod 0.25 mg; 0.5 mg
Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • The primary objective is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC). [ Time Frame: 32 weeks ] [ Designated as safety issue: Yes ]
    The primary objective is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).


Secondary Outcome Measures:
  • Evaluation of progression free survival [ Time Frame: 32 weeks ] [ Designated as safety issue: Yes ]
    Preliminary evidence of durable efficacy will be based on a modified PCWG2-defined radiologic progression-free survival including RECIST 1.1 criteria (PFS).

  • Preliminary evidence of efficacy will be determined by several criteria, one of which is PSA declines [ Time Frame: 32 weeks ] [ Designated as safety issue: Yes ]
    Preliminary evidence of response efficacy as measured by the rates of PSA decline (waterfall plot) and benchmarks of reaching a >30% decline within 3 months, a PSA decline >50% and >90%, and PSA normalization. Duration of PSA responses will be measured.

  • Preliminary evidence of efficacy will be determined by several criteria, one of which is circulating tumor cell changes over time [ Time Frame: 32 weeks ] [ Designated as safety issue: Yes ]
    Favorable changes in circulating tumor cell number (>=5 to <5) and proportion of men who achieve a reduction in CTC count will be a secondary endpoint which will be measured.

  • Measurement of the rates of radiographic response along with duration of responses. [ Time Frame: 32 weeks ] [ Designated as safety issue: Yes ]
    Radiologic response will be determined by criteria using RECIST 1.1 (overall response).


Estimated Enrollment: 32
Study Start Date: January 2012
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tasquinimod single dose Drug: tasquinimod
tasquinimod 0.25 mg continuously
Experimental: tasquinimod 0.25 mg followed by 0.5 mg
tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
Drug: tasquinimod 0.25 mg; 0.5 mg
tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
Experimental: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated

  Eligibility

Ages Eligible for Study:   18 Years to 79 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features;
  2. At least 18 years of age when signing the Informed Consent;
  3. Presence of metastatic disease on bone scan or CT/MRI imaging;
  4. Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., medical or surgical castration);
  5. For patients who have not had an orchiectomy, there must be a plan to maintain effective GnRH-analogue therapy for the duration of the trial;
  6. Serum testosterone level < 50 ng/dL at the Screening Visit;
  7. Progressive disease on or following docetaxel-based chemotherapy with medical or surgical castration. Patients who are intolerant of docetaxel are also allowed. Disease progression for study entry is defined as one or more of the following three criteria: 1) PSA progression defined by a minimum of three rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value at the Screening visit should be ≥ 2 μg/L (2 ng/mL); 2) Soft tissue disease progression defined by RECIST 1.1; 3) Bone metastatic disease progression defined by one or more new lesions on bone scan that are not clinically consistent with tumor flare;
  8. No more than three prior chemotherapy regimens with at least one regimen containing docetaxel (unless intolerant as per # 7 above);
  9. Karnofsky Performance Status of >70;
  10. Estimated life expectancy of at least three months;
  11. Able to swallow the study drug and comply with study requirements;
  12. Willing and able to give informed consent.

Exclusion Criteria:

  1. Subjects > 80 years old (dose escalation phase only, due to lower clearance in elderly patients);
  2. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment;
  3. Metastases in the brain or active epidural disease (NOTE: patients with treated epidural disease are allowed provided follow up imaging documents stability of epidural disease);
  4. Absolute neutrophil count < 1,200/μL, platelet count < 100,000/μL, and hemoglobin <9 g/dL at the Screening Visit; (NOTE: patients may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the Screening Visit)
  5. Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal at the Screening Visit;
  6. Creatinine > 1.5 x ULN at the Screening visit;
  7. History of another malignancy within the previous 3 years other than non-melanomatous skin cancer or non-invasive bladder cancer treated with curative intent;
  8. Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide, MDV3100), 5-α reductase inhibitors (finasteride, dutasteride), estrogens (ie DES), sipuleucel-T, or chemotherapy within 28 days of Day 1 visit or plans to initiate treatment with any of these treatments during the study;
  9. Use of herbal products that may decrease PSA levels or systemic corticosteroids greater than the equivalent of 10 mg of prednisone/prednisolone per day within four weeks of Day 1 visit;
  10. Ongoing treatment with warfarin unless the international normalized ratio (INR) is well controlled and below 4
  11. Exposure to ketoconazole or other strong CYP3A4 inhibitors or inducers intravenously or orally within 28 days prior to Day 1 Visit. For abiraterone acetate or TAK700, 14 days washout is needed.
  12. Ongoing treatment with sensitive CYP1A2 substrates or CYP1A2 substrates with narrow therapeutic range (Appendix 3).
  13. Ongoing treatment with CYP3A4 substrates with narrow therapeutic range (Appendix 3).
  14. Radiation therapy within 2 weeks (if single fraction of radiotherapy within 2 weeks) and radionuclide therapy within 8 weeks of Day 1 visit;
  15. Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery;
  16. Structurally unstable bone lesions suggesting impending fracture;
  17. Clinically significant cardiovascular disease including:myocardial infarction within 6 months, uncontrolled angina within 3 months, congestive heart failure, Diagnosed or suspected congenital long QT syndrome; significant ventricular arrhythmias, Prolonged corrected QT interval by the Fridericia or Bazett correction formula, History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place; Hypotension (systolic blood pressure < 86 mMHg or bradycardia with a heart rate < 50 beats per minute on any ECG taken at the Screening or Day 1 visit; Uncontrolled hypertension; TIA or stroke/CVA within 6 months of Day 1 visit; Rest limb claudication or ischemia within 6 months of Day 1 visit
  18. Use of an investigational agent within four weeks of Day 1 visit or plans to initiate treatment with an investigational agent during the study;
  19. Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last three months);
  20. Major surgery within four weeks prior to Day 1 visit.
  21. Presence of NCI CTC grade >1 peripheral neuropathy
  22. History of pancreatitis
  23. Known positive serology for HIV (patients with known history of HIV will be excluded because of potential for unforeseen toxicity and morbidity in an immunocompromised host).
  24. Chronic hepatitis B or C with advanced, decompensated hepatic disease, or cirrhosis of the liver or history of a chronic viral hepatitis or known viral hepatitis carrier (patients recovered from hepatitis will be allowed to enter the study).
  25. Documented prior disease progression on tasquinimod -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01513733

Contacts
Contact: Andrew Armstrong, MD 919-668-8108 andrew.armstrong@duke.edu

Locations
United States, Illinois
The University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Elia Martinez, RN    773-702-3623      
Principal Investigator: Russell Szmulewitz, MD         
United States, North Carolina
Duke Cancer Institute Recruiting
Durham, North Carolina, United States, 27710
Contact: Carol Winters, RN    919-668-8577    carol.winters@duke.edu   
Contact: Patricia Creel    919-668-0635    patricia.creel@duke.edu   
Sponsors and Collaborators
Andrew J. Armstrong, MD
Investigators
Principal Investigator: Andrew Armstrong, MD Duke Cancer Institute
  More Information

Additional Information:
No publications provided

Responsible Party: Andrew J. Armstrong, MD, Assoc Professor of Medicine, Duke University Medical Center
ClinicalTrials.gov Identifier: NCT01513733     History of Changes
Other Study ID Numbers: Pro00032421, c11-082
Study First Received: January 17, 2012
Last Updated: May 14, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on August 21, 2014